Mealey's (March 13, 2020, 10:35 AM EDT) -- TAMPA, Fla. — A federal judge in Florida on March 11 ruled that lead plaintiffs in a securities class action lawsuit against a medical technology company and its CEO have sufficiently pleaded the elements of their federal securities law claims in arguing that the defendants concealed negative clinical test results for the use of J-Plasma in cosmetic surgery (Kyle Pritchard v. Apyx Medical Corp., et al., No. 19-919, M.D. Fla., 2020 U.S. Dist. LEXIS 42627)....